Hormonal Acne: Causes, Patterns & How to Treat It

What Is Hormonal Acne?

Hormonal acne is acne that is predominantly driven or worsened by fluctuations in androgenic hormones — primarily testosterone and its more potent derivative dihydrotestosterone (DHT). These hormones stimulate sebaceous (oil) glands to enlarge and produce more sebum, setting off the four-factor cascade that produces every acne lesion: excess oil, abnormal follicular cell shedding, Cutibacterium acnes colonisation, and inflammation.

It is not a completely separate disease from acne vulgaris but rather a hormonally dominant subtype. The distinction matters because it guides treatment: standard topical therapy alone often delivers incomplete or short-lived results when an underlying androgen driver is unaddressed.

Who Gets Hormonal Acne?

Hormonal acne is most common in adult women, but it affects anyone with a functioning androgen pathway. Specific groups at elevated risk include:

• Adult women aged 25–40 — one of the most consistently described epidemiological features of adult acne; 20–40% of women who develop adult-onset acne do so after the age of 25.
• Women with PCOS — polycystic ovary syndrome accounts for more than 90% of cases of overall hyperandrogenism in women and is a leading cause of persistent adult acne.
• Perimenopausal women — as estrogen levels decline, the relative androgen influence on sebaceous glands increases.
• Pregnant and postpartum women — dramatic hormonal shifts can trigger new or worsened acne at any trimester and after delivery.
• Adolescents of all sexes — androgen surges at puberty are the primary reason acne peaks in the teenage years.
• Men on testosterone therapy or anabolic steroids — exogenous androgens strongly drive sebum overproduction and can trigger severe nodulo-cystic acne.

The Mechanism: Why Hormones Drive Acne

Androgen receptors are expressed in sebaceous glands, follicular keratinocytes, and dermal papilla cells. When testosterone and DHT bind these receptors:

1. Sebaceous glands enlarge and dramatically increase sebum output.
2. Follicular keratinocyte proliferation accelerates, forming the microcomedone plug.
3. The sebum-rich, anaerobic environment feeds C. acnes colonisation.
4. The resulting immune response produces inflammation — the redness, swelling, and pain of a breakout.

DHT is approximately five times more potent than testosterone at androgen receptors. It is formed locally in the skin by the enzyme 5α-reductase acting on circulating testosterone — meaning even women with normal circulating testosterone levels can have hormonally driven acne if their skin has high local 5α-reductase activity or receptor sensitivity.

Estrogen exerts a protective counter-effect: it down-regulates sebaceous gland activity and supports the skin barrier. The drop in estrogen relative to androgens — before menstruation, during perimenopause, or in PCOS — tips the balance toward acne.

The Menstrual Cycle Pattern

Many women notice a predictable monthly pattern: breakouts that worsen in the seven to ten days before menstruation (the luteal phase), when estrogen falls and progesterone dominates, then partly resolve after the period begins. This cyclical flare is a reliable clinical indicator of hormonally modulated acne.

How to Recognize Hormonal Acne: The Clinical Pattern

No laboratory test is required to diagnose hormonal acne in otherwise healthy women with a typical presentation. The following features together constitute the characteristic pattern:

Characteristic features:

• Lower-face predominance: Jaw, chin, neck, and occasionally the lower cheeks — the androgen-sensitive distribution.
• Inflammatory lesion type: Predominantly deep, tender papules and pustules rather than surface-level comedones (though blackheads and whiteheads can co-exist).
• Deep cystic lesions: Nodules and cysts concentrated on the jaw and chin in severe cases.
• Cyclical worsening: A reliable premenstrual flare pattern in women.
• Adult onset or persistence: Acne that begins or continues well beyond adolescence, particularly in women.

When it may indicate an underlying hormonal disorder:

Consult a dermatologist or endocrinologist for evaluation if acne is accompanied by any of the following:

• Irregular or absent menstrual cycles
• Excess facial or body hair (hirsutism)
• Scalp hair thinning or loss
• Unexplained weight gain, particularly around the abdomen
• Polycystic ovaries on imaging

These signs may indicate PCOS, congenital adrenal hyperplasia, or another endocrinopathy requiring targeted medical management beyond acne treatment alone.

Treatment: The Full Evidence-Based Ladder

Treatment is matched to severity and the role of hormonal factors. The AAD's 2024 updated guidelines for acne management inform this ladder.

Step 1 — Topical Therapy First

Standard topical acne treatments work for hormonal acne and are always the foundation:

• Topical retinoids (adapalene 0.1% OTC; prescription tretinoin, tazarotene, trifarotene): Normalize follicular cell turnover, prevent microcomedone formation, and reduce inflammation. First-line by AAD 2024 guidelines.
• Benzoyl peroxide (2.5%–10%): Kills C. acnes, reduces inflammation, and — critically — prevents the antibiotic resistance that can develop if antibiotics are used alone.
• Combination products: Fixed-dose combinations pairing adapalene with benzoyl peroxide outperform either ingredient used alone and are specifically recommended in the 2024 AAD guidelines.

For mild-to-moderate hormonal acne, a consistent topical routine — applied once daily at night — is the sensible starting point. Allow 8–12 weeks before judging results.

Step 2 — Topical Clascoterone (Anti-Androgen, Topical)

Clascoterone 1% cream is the first FDA-approved topical treatment that directly targets androgen receptors in the skin. It blocks testosterone and DHT from binding androgen receptors in sebaceous glands and follicular cells, reducing sebum output at the source without systemic hormonal effects. This makes it suitable for both males and females.

The 2024 AAD guidelines discuss clascoterone as an option addressing the hormonal pathway topically, with some experts noting it could be considered a first-line agent given its mechanism and safety profile. It can be combined with topical retinoids and benzoyl peroxide.

Step 3 — Systemic Hormonal Treatments (Women Only)

When topical therapy alone is insufficient and the patient is a woman not trying to conceive, systemic hormonal options are highly effective:

Combined Oral Contraceptives (COCs)

Three formulations are FDA-approved specifically for the treatment of acne in females:

• Norgestimate + ethinyl estradiol (Ortho Tri-Cyclen and generics)
• Norethindrone acetate + ethinyl estradiol (Estrostep Fe and generics)
• Drospirenone + ethinyl estradiol (Yaz and generics)

COCs reduce acne by suppressing ovarian androgen production and increasing sex hormone-binding globulin (SHBG), which binds free testosterone and reduces its availability to the skin. The AAD 2024 guidelines conditionally recommend COCs based on moderate-certainty evidence. Different formulations have generally similar efficacy; choice is guided by individual contraceptive needs, comorbidity profile, and access.

COCs are not appropriate for women with a personal or family history of estrogen-sensitive conditions, venous thromboembolism, migraines with aura, or smoking in women over 35. These contraindications require individual assessment.

Spironolactone

Spironolactone is an anti-androgen agent that has been used for acne for more than 30 years. It works through several mechanisms:

• Competes with testosterone and DHT at androgen receptors in the skin
• Inhibits 5α-reductase, reducing DHT formation
• Increases SHBG levels, lowering circulating free testosterone

Dose: Typically 50–100 mg/day for acne, with some patients benefiting from up to 200 mg/day. Higher doses carry greater risk of side effects (menstrual irregularity, breast tenderness, hyperkalemia) without proportionally greater benefit in most patients.

Efficacy: A retrospective study of 110 women reported an average 73% improvement in facial acne severity, with 55% achieving complete clearance. The AAD 2024 guidelines characterize spironolactone as a first-line treatment for women with acne, not merely a last resort.

Spironolactone is not appropriate for men — it blocks testosterone broadly and causes feminizing side effects including gynecomastia. Topical clascoterone addresses this gap for male patients.

Step 4 — Oral Isotretinoin for Severe Cases

For women (and men) with severe nodulo-cystic hormonal acne that is causing or threatening scarring, or that fails to respond adequately to the above measures, oral isotretinoin remains the most powerful option. It simultaneously reduces sebaceous gland size, normalizes follicular shedding, suppresses C. acnes, and dampens inflammation — achieving sustained long-term remission in approximately 80% of severe acne patients.

Isotretinoin requires strict prescriber monitoring and mandatory pregnancy prevention protocols (it is highly teratogenic). It is never a first-line option but is the right choice when acne is severe and unresponsive.

Hormonal Acne in Men

Men can develop hormonally driven acne, particularly:

• At puberty (androgen surge)
• During or after use of testosterone therapy or anabolic steroids
• In conditions causing elevated androgens (rare)

In men, spironolactone is not appropriate due to systemic anti-androgen effects. Topical clascoterone, topical retinoids, and benzoyl peroxide remain the backbone of treatment. Oral isotretinoin is used for severe cases.

Hormonal Acne and Skincare: What Helps, What Doesn't

The right skincare routine is a meaningful complement to treatment — not a replacement for it.

What helps:

• A gentle, non-comedogenic, fragrance-free cleanser twice daily
• A non-comedogenic lightweight moisturizer (acne-prone skin still needs hydration, especially when using drying actives)
• SPF 30+ every morning — retinoids and many acne treatments increase photosensitivity
• Avoiding heavy, occlusive foundations on the jawline and chin

What doesn't work:

• Over-cleansing or aggressive scrubbing — strips the skin barrier and worsens inflammation
• Spot-treating only — hormonal acne forms inside the follicle before it's visible; treatment should cover the whole acne-prone zone
• "Detox" products, facial steaming, or pore strips — no evidence of efficacy for hormonal acne
• Changing your diet alone — dietary modification (reducing high-glycemic foods) is a low-risk adjunct, but cannot address an androgen driver on its own

Lifestyle and Diet: A Supportive (Not Curative) Role

The evidence for specific lifestyle factors in acne has grown:

• High-glycemic-load diets raise insulin and IGF-1, which in turn stimulate androgen production in the skin and ovaries. Lowering glycemic load is the lifestyle change with the most consistent evidence for reducing acne lesion counts.
• Dairy consumption has been weakly associated with acne severity in cohort studies, possibly via whey protein driving IGF-1 and insulin. The evidence is less consistent than for glycemic load.
• Chronic stress activates the HPA axis and may increase adrenal androgen output (DHEA-S), potentially worsening hormonally driven acne. Stress management is a reasonable lifestyle measure.

These are adjuncts, not substitutes for evidence-based treatment.

When to See a Professional

See a dermatologist if:

• Acne includes nodules or cysts, or has caused any scarring
• Breakouts have not meaningfully improved after 2–3 months of consistent topical therapy
• Acne is accompanied by signs of a hormonal disorder (irregular cycles, hirsutism, unexplained weight gain, scalp hair loss)
• You want to explore hormonal treatment options (prescription required for most)
• Acne is significantly affecting mental health or quality of life

Early professional treatment dramatically reduces the risk of permanent acne scarring and can identify a treatable underlying condition.